Natera (NASDAQ:NTRA) Price Target Raised to $200.00 at JPMorgan Chase & Co.

Natera (NASDAQ:NTRA) had its price target boosted by JPMorgan Chase & Co. from $160.00 to $200.00 in a research report report published on Friday,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

A number of other analysts have also issued reports on NTRA. Sanford C. Bernstein raised their price target on Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Craig Hallum raised their price target on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. TD Cowen raised their price target on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Canaccord Genuity Group raised their price target on Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, The Goldman Sachs Group raised their price target on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $152.67.

Natera Stock Up 0.1 %

NTRA opened at $166.55 on Friday. The business’s fifty day moving average is $144.02 and its two-hundred day moving average is $124.66. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company has a market cap of $21.99 billion, a price-to-earnings ratio of -94.63 and a beta of 1.63. Natera has a one year low of $57.22 and a one year high of $175.63.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. During the same period in the prior year, the business earned ($0.95) earnings per share. The business’s revenue was up 63.9% on a year-over-year basis. Analysts anticipate that Natera will post -1.61 EPS for the current fiscal year.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 4,523 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $130.40, for a total transaction of $589,799.20. Following the sale, the chief executive officer now directly owns 191,163 shares in the company, valued at approximately $24,927,655.20. This trade represents a 2.31 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jonathan Sheena sold 2,700 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total value of $344,439.00. Following the sale, the insider now owns 284,741 shares in the company, valued at approximately $36,324,409.37. The trade was a 0.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 132,963 shares of company stock worth $21,250,107. 7.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Natera

Several hedge funds and other institutional investors have recently bought and sold shares of NTRA. Itau Unibanco Holding S.A. purchased a new stake in Natera during the 2nd quarter worth approximately $28,000. Quarry LP increased its holdings in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the last quarter. Covestor Ltd increased its holdings in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the last quarter. GAMMA Investing LLC increased its holdings in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after purchasing an additional 106 shares during the last quarter. Finally, True Wealth Design LLC purchased a new stake in Natera during the 3rd quarter worth approximately $57,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.